CU24184B1 - Profármaco de adrenomedulina basado en polietilenglicol - Google Patents
Profármaco de adrenomedulina basado en polietilenglicolInfo
- Publication number
- CU24184B1 CU24184B1 CUP2014000051A CU20140051A CU24184B1 CU 24184 B1 CU24184 B1 CU 24184B1 CU P2014000051 A CUP2014000051 A CU P2014000051A CU 20140051 A CU20140051 A CU 20140051A CU 24184 B1 CU24184 B1 CU 24184B1
- Authority
- CU
- Cuba
- Prior art keywords
- polyethylene glycol
- propharmacy
- adrenomeduline
- treatment
- prevention
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 3
- 230000006806 disease prevention Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002497 edematous effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
Abstract
La invención se refiere a un nuevo profármaco de adrenomedulina basado en polietilenglicol (PEG), a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades, y a su uso para producir medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente trastornos cardiovasculares, edematosos y/o inflamatorios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11187735 | 2011-11-03 | ||
| PCT/EP2012/071507 WO2013064508A1 (en) | 2011-11-03 | 2012-10-30 | Polyethylene glycol based prodrug of adrenomedullin and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20140051A7 CU20140051A7 (es) | 2014-10-02 |
| CU24184B1 true CU24184B1 (es) | 2016-07-29 |
Family
ID=47146369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2014000051A CU24184B1 (es) | 2011-11-03 | 2014-04-29 | Profármaco de adrenomedulina basado en polietilenglicol |
Country Status (45)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150000464A (ko) * | 2011-11-03 | 2015-01-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커 |
| EP2896400A1 (en) * | 2014-01-17 | 2015-07-22 | Université Catholique De Louvain | Method for increasing the bioavailability of inhaled compounds |
| CN106164088B (zh) * | 2014-03-20 | 2021-11-23 | 国立大学法人宫崎大学 | 长效肾上腺髓质素衍生物 |
| AP2017009826A0 (en) * | 2014-09-26 | 2017-03-31 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
| NZ740534A (en) | 2015-09-18 | 2019-07-26 | Univ Miyazaki | Long-acting adrenomedullin derivative |
| EP3604538A4 (en) * | 2017-03-29 | 2020-12-30 | University of Miyazaki | LONG-ACTING ADRENOMEDULLINE DERIVATIVE |
| GB201707938D0 (en) * | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| EP3986918A1 (en) | 2019-06-18 | 2022-04-27 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| MX2022003407A (es) * | 2019-09-21 | 2022-07-04 | Ixaka France | Síntesis sin dmso de poli(beta-aminoéster)es modificados con oligopéptidos y su uso en sistemas de suministro de nanopartículas. |
| JP7498882B2 (ja) * | 2019-12-05 | 2024-06-13 | 国立大学法人 宮崎大学 | 異常タンパク質蓄積性神経変性疾患の治療剤 |
| CN115484987A (zh) * | 2020-04-03 | 2022-12-16 | 拜耳公司 | 液体药物制剂聚乙二醇基肾上腺髓质素前药和用途 |
| MX2022012318A (es) | 2020-04-03 | 2022-10-27 | Bayer Ag | Formulaciones farmaceuticas de profarmacos de adrenomedulina a base de polietilenglicol y uso. |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| CN112457218B (zh) * | 2020-11-05 | 2022-08-09 | 宁夏医科大学 | 2,4-二氨基丁酸衍生物的合成方法 |
| KR20240046872A (ko) | 2021-08-20 | 2024-04-11 | 바이엘 악티엔게젤샤프트 | Peg화 아드레노메둘린의 제조 방법, 그의 중간체 및 그의 용도 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2025133215A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Use of inactive adrenomedullin precursor for therapeutic purposes |
| WO2025133225A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5020040A (en) * | 1987-06-24 | 1991-05-28 | Digital Equipment Corporation | Overwriting system for magneto-optical recording with self timing track |
| US4812590A (en) * | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CA2292902C (en) | 1999-12-24 | 2012-12-18 | Alain Cadieux | Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20050271615A1 (en) | 2002-08-30 | 2005-12-08 | Doron Shabat | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
| WO2005009768A1 (en) | 2003-07-23 | 2005-02-03 | Meggitt Aerospace Equipment | Composite seal |
| WO2005099768A2 (en) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| WO2005116065A1 (en) | 2004-05-24 | 2005-12-08 | Institut De Cardiologie De Montréal | Labelled adrenomedullin derivatives and their use for imaging and therapy |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| JP2010513476A (ja) * | 2006-12-20 | 2010-04-30 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| WO2008138141A1 (en) * | 2007-05-11 | 2008-11-20 | Institut De Cardiologie De Montréal | Labelled adrenomedullin derivatives and their use for imaging and therapy. |
| WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| KR20150000464A (ko) * | 2011-11-03 | 2015-01-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커 |
-
2011
- 2011-11-03 JO JOP/2019/0001A patent/JOP20190001B1/ar active
-
2012
- 2012-10-24 JO JOP/2012/0324A patent/JO3385B1/ar active
- 2012-10-29 UY UY0001034419A patent/UY34419A/es unknown
- 2012-10-29 UY UY0001037922A patent/UY37922A/es active IP Right Grant
- 2012-10-30 PH PH1/2014/500998A patent/PH12014500998A1/en unknown
- 2012-10-30 BR BR112014010708-4A patent/BR112014010708B1/pt not_active IP Right Cessation
- 2012-10-30 RS RS20180141A patent/RS56819B1/sr unknown
- 2012-10-30 SG SG10201607516SA patent/SG10201607516SA/en unknown
- 2012-10-30 CN CN201610837728.9A patent/CN107412740B/zh not_active Expired - Fee Related
- 2012-10-30 KR KR1020187027464A patent/KR102004668B1/ko not_active Expired - Fee Related
- 2012-10-30 PL PL15192265T patent/PL3075395T3/pl unknown
- 2012-10-30 HU HUE15192265A patent/HUE036535T2/hu unknown
- 2012-10-30 IN IN3290CHN2014 patent/IN2014CN03290A/en unknown
- 2012-10-30 SG SG11201400924TA patent/SG11201400924TA/en unknown
- 2012-10-30 CN CN201280053588.6A patent/CN103998063B/zh not_active Expired - Fee Related
- 2012-10-30 UA UAA201405818A patent/UA111098C2/uk unknown
- 2012-10-30 KR KR1020147013845A patent/KR101965467B1/ko not_active Expired - Fee Related
- 2012-10-30 EP EP15192265.5A patent/EP3075395B1/en active Active
- 2012-10-30 MY MYPI2014701087A patent/MY173372A/en unknown
- 2012-10-30 DK DK15192265.5T patent/DK3075395T3/en active
- 2012-10-30 LT LTEP15192265.5T patent/LT3075395T/lt unknown
- 2012-10-30 US US14/355,568 patent/US9603936B2/en not_active Expired - Fee Related
- 2012-10-30 MX MX2014004384A patent/MX350341B/es active IP Right Grant
- 2012-10-30 MX MX2017011334A patent/MX361287B/es unknown
- 2012-10-30 SI SI201231218T patent/SI3075395T1/en unknown
- 2012-10-30 MY MYPI2018001427A patent/MY194197A/en unknown
- 2012-10-30 NO NO15192265A patent/NO3075395T3/no unknown
- 2012-10-30 EA EA201400528A patent/EA025631B1/ru not_active IP Right Cessation
- 2012-10-30 DK DK12783566.8T patent/DK2773376T3/en active
- 2012-10-30 AR ARP120104059A patent/AR088582A1/es not_active Application Discontinuation
- 2012-10-30 SI SI201230498A patent/SI2773376T1/sl unknown
- 2012-10-30 EA EA201600495A patent/EA029410B1/ru not_active IP Right Cessation
- 2012-10-30 RS RS20160172A patent/RS54623B1/sr unknown
- 2012-10-30 JP JP2014539315A patent/JP5995984B2/ja not_active Expired - Fee Related
- 2012-10-30 HR HRP20160285TT patent/HRP20160285T1/hr unknown
- 2012-10-30 PE PE2018001536A patent/PE20181493A1/es unknown
- 2012-10-30 PE PE2014000540A patent/PE20141219A1/es active IP Right Grant
- 2012-10-30 TR TR2018/02124T patent/TR201802124T4/tr unknown
- 2012-10-30 ME MEP-2016-56A patent/ME02379B/me unknown
- 2012-10-30 WO PCT/EP2012/071507 patent/WO2013064508A1/en not_active Ceased
- 2012-10-30 AU AU2012331244A patent/AU2012331244B2/en not_active Ceased
- 2012-10-30 ES ES15192265.5T patent/ES2659195T3/es active Active
- 2012-10-30 PL PL12783566T patent/PL2773376T3/pl unknown
- 2012-10-30 ES ES12783566.8T patent/ES2568063T3/es active Active
- 2012-10-30 EP EP12783566.8A patent/EP2773376B1/en active Active
- 2012-10-30 CA CA2854134A patent/CA2854134C/en active Active
- 2012-10-30 PT PT151922655T patent/PT3075395T/pt unknown
- 2012-10-30 HU HUE12783566A patent/HUE027333T2/en unknown
- 2012-11-02 TW TW101140660A patent/TWI583396B/zh not_active IP Right Cessation
- 2012-11-02 TW TW106104340A patent/TWI653051B/zh not_active IP Right Cessation
-
2014
- 2014-04-09 IL IL232037A patent/IL232037B/en active IP Right Grant
- 2014-04-10 CO CO14078051A patent/CO7020863A2/es unknown
- 2014-04-14 CL CL2014000948A patent/CL2014000948A1/es unknown
- 2014-04-15 DO DO2014000078A patent/DOP2014000078A/es unknown
- 2014-04-23 CR CR20140184A patent/CR20140184A/es unknown
- 2014-04-28 EC ECSP14013326 patent/ECSP14013326A/es unknown
- 2014-04-28 MA MA36961A patent/MA35618B1/fr unknown
- 2014-04-29 CU CUP2014000051A patent/CU24184B1/es active IP Right Grant
- 2014-04-30 TN TNP2014000185A patent/TN2014000185A1/en unknown
- 2014-04-30 GT GT201400085A patent/GT201400085A/es unknown
-
2015
- 2015-12-31 US US14/986,488 patent/US9649363B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 ZA ZA2016/00434A patent/ZA201600434B/en unknown
- 2016-04-12 CY CY20161100293T patent/CY1117354T1/el unknown
- 2016-08-23 JP JP2016162327A patent/JP6177975B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-29 US US15/472,476 patent/US10035818B2/en active Active
- 2017-05-15 IL IL252281A patent/IL252281B/en active IP Right Grant
- 2017-05-22 AU AU2017203423A patent/AU2017203423B2/en not_active Ceased
-
2018
- 2018-02-07 CY CY20181100151T patent/CY1119897T1/el unknown
- 2018-02-21 HR HRP20180319TT patent/HRP20180319T1/hr unknown
- 2018-03-19 IL IL258229A patent/IL258229B/en active IP Right Grant
- 2018-09-20 EC ECSENADI201871104A patent/ECSP18071104A/es unknown
- 2018-09-20 DO DO2018000203A patent/DOP2018000203A/es unknown
- 2018-11-05 AR ARP180103212A patent/AR113830A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000203A (es) | Profármaco de adrenomedulina basado en polietilenglicol y su uso | |
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CY1120219T1 (el) | Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων | |
| IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| CL2013003333A1 (es) | Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras. | |
| BR112013020383A2 (pt) | formulações liofilizadas. | |
| IT1402018B1 (it) | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. | |
| CY1119446T1 (el) | Φαρμακοτεχνικες μορφες δαρουναβιρης | |
| NI201700036A (es) | Derivados estabilizados de adrenomedulina y uso de los mismos. | |
| CL2014000484A1 (es) | Compuestos derivados del acido pirrolidin-3-il-acetico; composicion farmaceutica que los comprende y uso en el tratamiento de la enfermedad inflamatoria del intestino. | |
| CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
| DOP2015000290A (es) | Benzoxazoles sustituidos | |
| HN2010001125A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| TR201106224A2 (tr) | Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler. | |
| ES1075570Y (es) | Plataforma deslizante para patinar de pie o sentado. | |
| BR112015003372A2 (pt) | composição de conjugado , e , uso de uma composição. | |
| CL2014001457A1 (es) | Nuevos derivados de azetidina , composiciones farmaceuticas y sus usos . | |
| ES1074681Y (es) | Muneco para juegos de tablas de monopatin de dedos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |